I-Lenvatinib Mesylate Intermediate CAS 205448-65-3 Ubumsulwa >98.0% (HPLC) Factory

Incazelo emfushane:

Igama Lekhemikhali: Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate

I-CAS: 205448-65-3

Ubumsulwa: >98.0% (HPLC)

Ukubukeka: Okumhlophe Okumhlophe ukuya Kokuphuzi

I-Intermediate ye-Lenvatinib Mesylate CAS 857890-39-2

E-Mail: alvin@ruifuchem.com


Imininingwane Yomkhiqizo

Imikhiqizo Ehlobene

Omaka bomkhiqizo

Incazelo:

Chemical Properties:

Igama Lekhemikhali I-Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate
Omqondofana I-1,4-Dihydro-7-Methoxy-4-Oxo-6-Quinolinecarboxylic Acid Methyl Ester;I-7-Methoxy-4-Oxo-1,4-Dihydro-Quinoline-6-Carboxylic Acid Methyl Ester;I-Lenvatinib Intermediate 3
Inombolo ye-CAS 205448-65-3
Inombolo yeCAT I-RF-PI1973
Isimo Sesitoko Esitokweni, Amandla Okukhiqiza 50 MT/Unyaka
I-Molecular Formula I-C12H11NO4
Isisindo samangqamuzana 233.22
Iphuzu elibilayo 421.0±45.0℃
Ukuminyana 1.267±0.060 g/cm3
Ibhrendi I-Ruifu Chemical

Imininingwane:

Into Imininingwane
Ukubukeka I-Off-White to Yellowish Powder
Ukuhlanzeka / Indlela Yokuhlaziya >98.0% (HPLC)
Ukulahlekelwa Ekumisweni <1.00%
Izinsalela ekushiseni <0.50%
Ukungcola Okuphelele <2.00%
H-NMR Ivumelana Nesakhiwo
Izinga Lokuhlola I-Enterprise Standard
Ukusetshenziswa Pharmaceutical Intermediates

Iphakheji nesitoreji:

Iphakheji: Ibhodlela, isikhwama se-Aluminium foil, 25kg/Cardboard Drum, noma ngokwemfuneko yekhasimende

Isimo Sesitoreji:Gcina ezitsheni ezivaliwe endaweni epholile neyomile;Vikela ekukhanyeni nakumswakama

Izinzuzo:

1

I-FAQ:

Isicelo:

I-Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate (CAS: 205448-65-3) iphakathi kwe-Lenvatinib Mesylate (CAS: 857890-39-2).I-Lenvatinib, ethengiswa ngaphansi kwegama lomkhiqizo elithi Lenvima phakathi kokunye, umuthi wokulwa nomdlavuza wokwelapha izinhlobo ezithile zomdlavuza wegilo kanye neminye imidlavuza.Yakhiwe yi-Eisai Co. futhi isebenza njenge-multiple kinase inhibitor ngokumelene ne-VEGFR1, VEGFR2 kanye ne-VEGFR3 kinases.I-Lenvatinib ivunyelwe (kusukela ngo-2015) yokwelashwa komdlavuza we-thyroid ohlukile ophindeka endaweni noma we-metastatic, oqhubekayo, futhi ongaphenduli ekwelashweni nge-radioiodine (radioiodine).NgoMeyi 2016, i-US Food and Drug Administration (FDA) yagunyaza (ngokuhambisana ne-everolimus) ukuze zelashwe i-renal cell carcinoma ethuthukisiwe kulandela ukwelashwa okukodwa kwangaphambili kokulwa ne-angiogenic.Umuthi ugunyazwe nase-US nase-European Union nge-hepatocellular carcinoma engakwazi ukususwa ngokuhlinzwa ezigulini ezingazange zithole ukwelashwa komdlavuza ngomlomo noma ngomjovo.

Bhala umyalezo wakho lapha futhi usithumelele wona